Neal Shore discusses the ARASENS trial’s post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the evidence that combining ADT, docetaxel, and darolutamide significantly delays resistant disease development and extends survival. Dr. Shore highlights the shift away from monotherapy ADT towards comprehensive treatment…
Lisa Bancroft is among thousands of people who have been tested for the faulty BRCA gene since its discovery 30 years ago.
Zach Klaassen facilitates a conversation on the continuum of care in metastatic hormone-sensitive prostate cancer (mHSPC) with Jason Hafron and Elisabeth Heath. The discussion underscores…
Jason Efstathiou discusses the PARTIQoL trial, a randomized phase III study comparing proton beam therapy to IMRT for localized prostate cancer. Dr. Efstathiou discusses the…
The trust says that alternative car parks will be open as normal for patients and visitors.
About this episode: CRISPR technology can edit genetic codes, making it possible to cure people of terrible diseases, among other uses. But its power is…
Alicia Morgans hosts a discussion with Paul Eber and Brad Somer to explore the collaborative management of metastatic hormone-sensitive prostate cancer cases. They highlight a…
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Bone Health Management for Advanced Prostate Cancer – Fred Saad Part…
As President-elect Donald Trump’s transition team vets candidates for key healthcare positions, pharmaceutical industry sources said the following people are possible appointees:
Ruchika Talwar hosts a discussion with Greg Tasian and Nicolas Fernandez about surgical variations in managing pediatric kidney stone disease. They discuss the PKIDS study,…
stone disease, kidney stones, percutaneous nephrolithotomy (PCNL), stone-free rate (SFR), Pediatric Percutaneous Nephrolithotomy, pediatric urology, ultrasonography.
